News headlines about Biodel (NASDAQ:ALBO) have been trending somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Biodel earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.533968451924 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Biodel (ALBO) opened at 27.35 on Thursday. The firm’s 50-day moving average price is $21.13 and its 200 day moving average price is $21.50. The company’s market capitalization is $172.09 million. Biodel has a 12-month low of $9.90 and a 12-month high of $37.69.
Biodel (NASDAQ:ALBO) last released its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.10) by $0.04. On average, equities research analysts expect that Biodel will post ($3.77) EPS for the current fiscal year.
Several equities analysts have weighed in on the company. Needham & Company LLC assumed coverage on Biodel in a report on Tuesday. They set a “buy” rating and a $35.00 target price on the stock. Zacks Investment Research upgraded Biodel from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a report on Tuesday, July 11th. Finally, Wedbush assumed coverage on Biodel in a report on Friday, June 30th. They set an “outperform” rating on the stock. Five investment analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average price target of $31.50.
TRADEMARK VIOLATION WARNING: “Biodel (NASDAQ:ALBO) Receiving Somewhat Positive News Coverage, Report Finds” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://stocknewstimes.com/2017/07/20/biodel-nasdaqalbo-receiving-somewhat-positive-news-coverage-report-finds.html.
Biodel Company Profile
Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.
Receive News & Ratings for Biodel Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodel Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
